Priser
Platform
Blog
Om os
Download
301333
R&G PharmaStudies Co
Shenzhen Stock Exchange
0

Om

R&G Pharmastudies Co. Ltd. operates as a pivotal entity in the pharmaceutical sector, primarily focusing on the research, development, and innovation of medical technology and drug treatment solutions. Its central function revolves around providing comprehensive pharmacological studies, which serve a critical role in understanding drug efficacy and safety before reaching the market. The company plays a significant role in the pharmaceutical and healthcare industries, contributing significantly to scientific advancements and the development of new therapies. Through its extensive experiments and clinical trials, R&G Pharmastudies ensures rigorous adherence to regulatory standards, aiding pharmaceutical companies in bringing new drugs to market efficiently and safely. This company acts as a cornerstone in the pharmaceutical supply chain, facilitating the transition of drugs from laboratory discovery to commercial availability, ultimately impacting global healthcare by enabling medical progress and innovation.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I R&G PHARMASTUDIES CO MED ENDAVU: Køb R&G PharmaStudies Co ($301333) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i R&G PharmaStudies Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

Ticker301333
Land
Kina
Antal medarbejdere2.645
Hjemmesiderg-pharma.com
SektorSundhed
IndustriBioteknologi

Udbytter

0,2CNH
'24
0,16CNH
'25
Ex-udbytte-dato8. jul. 2025
Udbytteafkast0,26%

Analytikerskøn

Baseret på 1 analytiker

Stærkt købKøbHoldSælgStærkt sælg
0%100%0%0%0%